公开(公告)号：EP1318995A2

公开(公告)日：2003-06-18

申请号：EP01980812.0

申请日：2001-09-18

申请人： CENTRE NATIONAL DELA RECHERCHE SCIENTIFIQUE (CNRS) ,  Institut Curie

发明人： GUILLEMONT, Jérôme ,  BENJAHAD, Abdellah ,  MABIRE, Dominique ,  N'GUYEN, Chi, Hung ,  GRIERSON, David ,  MONNERET, Claude ,  BISAGNI, Emile ,  SANZ, Gérard ,  DECRANE, Laurence

IPC分类号： C07D401/12 ,  C07D213/78 ,  C07D407/06 ,  C07D417/06 ,  C07D401/06 ,  C07D213/71 ,  C07D405/04 ,  C07D213/82 ,  C07D213/70 ,  C07D213/69 ,  C07D409/12 ,  C07D417/12 ,  C07D405/12 ,  C07D491/04 ,  C07D215/22

CPC分类号： C07D213/64 ,  C07D213/69 ,  C07D213/70 ,  C07D213/71 ,  C07D213/78 ,  C07D213/80 ,  C07D213/82 ,  C07D213/85 ,  C07D213/89 ,  C07D215/22 ,  C07D215/227 ,  C07D215/36 ,  C07D401/06 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D407/04 ,  C07D407/06 ,  C07D407/12 ,  C07D407/14 ,  C07D409/04 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D417/12 ,  C07D491/04

摘要： The present invention is concerned among others with compounds of formula (1), the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and stereochemically isomeric forms thereof, wherein Q is halo, C1-6 alkyl or C2-6 alkenyl; X is (a-2) with q and r being O and Z being O, S or SO; R1 is aryl; R2 is selected from formyl; C1-6alkyloxycarbonylalkyl; Het?2; Het2C¿1-6alkyl, C1-6alkylthio; C1-6alkyl optionally substituted with one or two substituents each independently selected from hydroxy, and halo; R3 is selected from formyl; C1-6alkyl optionally substituted with one or two C1-6alkyloxy; R4 is hydrogen, with HIV inhibiting properties.

公开(公告)号：EP1318995B1

公开(公告)日：2006-03-08

申请号：EP01980812.0

申请日：2001-09-18

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  Institut Curie

发明人： GUILLEMONT, Jérôme ,  BENJAHAD, Abdellah ,  MABIRE, Dominique ,  N'GUYEN, Chi, Hung ,  GRIERSON, David ,  MONNERET, Claude ,  BISAGNI, Emile ,  SANZ, Gérard ,  DECRANE, Laurence

IPC分类号： C07D401/12 ,  C07D213/78 ,  C07D407/06 ,  C07D417/06 ,  C07D401/06 ,  C07D213/71 ,  C07D405/04 ,  C07D213/82 ,  C07D213/70 ,  C07D213/69 ,  C07D409/12 ,  C07D417/12 ,  C07D405/12 ,  C07D491/04 ,  C07D215/22

CPC分类号： C07D213/64 ,  C07D213/69 ,  C07D213/70 ,  C07D213/71 ,  C07D213/78 ,  C07D213/80 ,  C07D213/82 ,  C07D213/85 ,  C07D213/89 ,  C07D215/22 ,  C07D215/227 ,  C07D215/36 ,  C07D401/06 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D407/04 ,  C07D407/06 ,  C07D407/12 ,  C07D407/14 ,  C07D409/04 ,  C07D409/12 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D417/12 ,  C07D491/04

摘要： The present invention is concerned among others with compounds of formula (1), the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and stereochemically isomeric forms thereof, wherein Q is halo, C1-6 alkyl or C2-6 alkenyl; X is (a-2) with q and r being O and Z being O, S or SO; R1 is aryl; R2 is selected from formyl; C1-6alkyloxycarbonylalkyl; Het?2; Het2C¿1-6alkyl, C1-6alkylthio; C1-6alkyl optionally substituted with one or two substituents each independently selected from hydroxy, and halo; R3 is selected from formyl; C1-6alkyl optionally substituted with one or two C1-6alkyloxy; R4 is hydrogen, with HIV inhibiting properties.